You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCabazitaxel
Accession NumberDB06772
TypeSmall Molecule
GroupsApproved
DescriptionCabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010.
Structure
Thumb
Synonyms
Cabazitaxelum
Taxoid XRP6258
TXD258
XRP6258
External Identifiers
  • RPR-116258A
  • RPR116258
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JevtanaSolution40 mgIntravenousSanofi Aventis Canada Inc2011-08-23Not applicableCanada
JevtanaKitSanofi Aventis U.S. Llc2010-06-17Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII51F690397J
CAS number183133-96-2
WeightAverage: 835.9324
Monoisotopic: 835.377905537
Chemical FormulaC45H57NO14
InChI KeyBMQGVNUXMIRLCK-OAGWZNDDSA-N
InChI
InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][C@@](O)([C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1)C(=O)O[C@@]1([H])C[C@@]2(O)[C@@]([H])(OC(=O)C3=CC=CC=C3)[C@]3([H])[C@@]4(CO[C@]4([H])C[C@]([H])(OC)[C@@]3(C)C(=O)[C@]([H])(OC)C(=C1C)C2(C)C)OC(C)=O
Pharmacology
IndicationFor treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Structured Indications
PharmacodynamicsCabaitaxel has anti-tumour properties and is effective against docetaxel-sensitive and -insensitive tumours.
Mechanism of actionCabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the interference of mitotic and interphase cellular functions. The cell is then unable to progress further into the cell cycle, being stalled at metaphase, thus triggering apoptosis of the cancer cell.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tubulin alpha-4A chainProteinyes
binder
HumanP68366 details
Tubulin beta-1 chainProteinyes
binder
HumanQ9H4B7 details
Related Articles
AbsorptionAfter an intravenous dose of cabazitaxel 25 mg/m2 every three weeks to a population of 170 patients with solid tumors, the mean Cmax in patients with metastatic prostate cancer was 226 ng/mL (CV 107%) and was reached at the end of the one-hour infusion (Tmax). The mean AUC in patients with metastatic prostate cancer was 991 ng.h/mL (CV 34%). Administration with prednisone or prednisolone do not effect the pharmacokinetic profile of cabazitaxel.
Volume of distribution

The volume of distribution (Vss) was 4,864 L (2,643 L/m2 for a patient with a median BSA of 1.84 m2) at steady state. Compared to other taxanes, penetrates the CNS to a greater extent.

Protein bindingCabazitaxel is mainly bound to human serum albumin (82%) and lipoproteins (88% for HDL, 70% for LDL, and 56% for VLDL).
Metabolism

Cabazitaxel is extensively metabolized in the liver (>95%), mainly by the CYP3A4/5 isoenzyme (80% to 90%), and to a lesser extent by CYP2C8 which results in 20 different metabolites. Two of these metabolites are active demethylated derivatives of cabaxitaxel and referred to as RPR112698 and RPR123142 respectively. Docetaxel is another metabolite of cabazitaxel. Cabazitaxel is the main circulating moiety in human plasma.

SubstrateEnzymesProduct
Cabazitaxel
Not Available
DocetaxelDetails
Cabazitaxel
Not Available
RPR112698Details
Cabazitaxel
Not Available
RPR123142Details
Route of eliminationAfter a one-hour intravenous infusion [14C]-cabazitaxel 25 mg/m2, approximately 80% of the administered dose was eliminated within 2 weeks. Cabazitaxel is mainly excreted in the feces as numerous metabolites (76% of the dose); while renal excretion of cabazitaxel and metabolites account for 3.7% of the dose (2.3% as unchanged drug in urine).
Half lifeFollowing a one-hour intravenous infusion, plasma concentrations of cabazitaxel can be described by a three-compartment pharmacokinetic model with α-, β-, and γ- half-lives of 4 minutes, 2 hours, and 95 hours, respectively.
Clearance

Cabazitaxel has a plasma clearance of 48.5 L/h (CV 39%; 26.4 L/h/m2 for a patient with a median BSA of 1.84 m2) in patients with metastatic prostate cancer.

ToxicityCabazitaxel may cause serious side effects including neutropenia, hypersensitivity reactions, gastrointestinal symptoms, and renal failure. Anticipated complications of overdose include exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders. Cabazitaxel penetrates the blood-brain barrier. LD50, rat = 500 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 2-Methoxyestradiol.Investigational
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 3-Methoxybenzamide.Experimental
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 3,4-Dihydroxybenzoic Acid.Experimental
5,10-Dideazatetrahydrofolic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 5,10-Dideazatetrahydrofolic Acid.Experimental
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 7-Hydroxystaurosporine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 8-azaguanine.Experimental
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.Investigational
AbirateroneThe serum concentration of Cabazitaxel can be increased when it is combined with Abiraterone.Approved
ABT-263The risk or severity of adverse effects can be increased when Cabazitaxel is combined with ABT-263.Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Cabazitaxel.Approved
AcetaminophenThe serum concentration of Cabazitaxel can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Cabazitaxel.Approved, Vet Approved
AclarubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aclarubicin.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Acteoside.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cabazitaxel.Approved
AfimoxifeneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Afimoxifene.Investigational
AfliberceptThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aflibercept.Approved
AlatrofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alatrofloxacin.Withdrawn
AlbendazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Cabazitaxel can be increased when it is combined with Alectinib.Approved
AlemtuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alemtuzumab.Approved, Investigational
AlfentanilThe serum concentration of Cabazitaxel can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alitretinoin.Approved, Investigational
Alpha-DifluoromethylornithineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alpha-Difluoromethylornithine.Experimental
ALT-110The risk or severity of adverse effects can be increased when Cabazitaxel is combined with ALT-110.Investigational
AltretamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Altretamine.Approved
AmantadineThe serum concentration of Cabazitaxel can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Cabazitaxel.Approved, Investigational
Amg 386The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amg 386.Investigational
AminocamptothecinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aminocamptothecin.Investigational
AminoglutethimideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aminoglutethimide.Approved
Aminohippuric acidThe serum concentration of Cabazitaxel can be increased when it is combined with Aminohippuric acid.Approved
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Cabazitaxel can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Cabazitaxel can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Cabazitaxel can be increased when it is combined with Amlodipine.Approved
AmonafideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amonafide.Investigational
AmprenavirThe serum concentration of Cabazitaxel can be decreased when it is combined with Amprenavir.Approved
AmrubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amrubicin.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Amsacrine.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anagrelide.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anastrozole.Approved, Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anecortave.Investigational
annamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with annamycin.Investigational
AnvirzelAnvirzel may decrease the cardiotoxic activities of Cabazitaxel.Investigational
AP 12009The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AP 12009.Investigational
AP24534The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AP24534.Investigational
ApaziquoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Apaziquone.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Cabazitaxel.Approved
AprepitantThe serum concentration of Cabazitaxel can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Arsenic trioxide.Approved, Investigational
ASA404The risk or severity of adverse effects can be increased when Cabazitaxel is combined with ASA404.Investigational
AsparaginaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Asparaginase.Approved
AstemizoleThe serum concentration of Cabazitaxel can be increased when it is combined with Astemizole.Approved, Withdrawn
AT-101The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AT-101.Investigational
AtazanavirThe serum concentration of Cabazitaxel can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Cabazitaxel can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Cabazitaxel can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Cabazitaxel can be increased when it is combined with Atorvastatin.Approved
AxitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Axitinib.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azathioprine.Approved
AZD2171The risk or severity of adverse effects can be increased when Cabazitaxel is combined with AZD2171.Investigational
Azd4547The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azd4547.Investigational
Azelaic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Azelaic Acid.Approved
AzelastineThe serum concentration of Cabazitaxel can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Cabazitaxel can be increased when it is combined with Azithromycin.Approved
BatimastatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Batimastat.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Cabazitaxel.Investigational
BelinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Belinostat.Approved, Investigational
BelotecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Belotecan.Investigational
BendamustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bendamustine.Approved, Investigational
BenzocaineThe serum concentration of Cabazitaxel can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Cabazitaxel can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Besifloxacin.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Cabazitaxel.Approved, Vet Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Betulinic Acid.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Cabazitaxel.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bexarotene.Approved, Investigational
Bgj398The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bgj398.Investigational
BicalutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bicalutamide.Approved
BiperidenThe serum concentration of Cabazitaxel can be increased when it is combined with Biperiden.Approved
BizelesinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bizelesin.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Blinatumomab.Approved
Bmn 673The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bmn 673.Investigational
BoceprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cabazitaxel can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cabazitaxel.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cabazitaxel.Approved
BromocriptineThe serum concentration of Cabazitaxel can be increased when it is combined with Bromocriptine.Approved, Investigational
BroxuridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Broxuridine.Investigational
Bryostatin 1The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bryostatin 1.Investigational
BSI-201The risk or severity of adverse effects can be increased when Cabazitaxel is combined with BSI-201.Investigational
BuprenorphineThe serum concentration of Cabazitaxel can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Cabazitaxel can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Busulfan.Approved, Investigational
Buthionine SulfoximineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Buthionine Sulfoximine.Investigational
CabergolineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cabergoline.Approved
CabozantinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cabozantinib.Approved
CaffeineThe serum concentration of Cabazitaxel can be increased when it is combined with Caffeine.Approved
CaiThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cai.Investigational
CalcipotriolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Calcipotriol.Approved
CamptothecinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Camptothecin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Cabazitaxel.Approved
CandesartanThe serum concentration of Cabazitaxel can be increased when it is combined with Candesartan.Approved
CapecitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Cabazitaxel can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Cabazitaxel can be increased when combined with Carbamazepine.Approved, Investigational
CarboplatinCarboplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
CarfilzomibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carfilzomib.Approved
CarmofurThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carmofur.Withdrawn
CarmustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Carmustine.Approved
CarvedilolThe serum concentration of Cabazitaxel can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Cabazitaxel can be increased when it is combined with Caspofungin.Approved
CatumaxomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Catumaxomab.Investigational
CB1954The risk or severity of adverse effects can be increased when Cabazitaxel is combined with CB1954.Experimental
CDX-110The risk or severity of adverse effects can be increased when Cabazitaxel is combined with CDX-110.Investigational
CediranibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cediranib.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Cabazitaxel can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Cabazitaxel.Withdrawn
CetuximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Chlorambucil.Approved
ChloroquineThe serum concentration of Cabazitaxel can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Chlorotrianisene.Withdrawn
ChlorpromazineThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Cabazitaxel can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Cabazitaxel can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Cabazitaxel can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Cabazitaxel can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ciprofloxacin.Approved, Investigational
CisplatinCisplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
CitalopramThe serum concentration of Cabazitaxel can be increased when it is combined with Citalopram.Approved
CladribineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Cabazitaxel can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Cabazitaxel can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Cabazitaxel.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Cabazitaxel can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Cabazitaxel.Approved, Investigational
ClomipramineThe serum concentration of Cabazitaxel can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Cabazitaxel.Approved
ClopidogrelThe metabolism of Cabazitaxel can be decreased when combined with Clopidogrel.Approved, Nutraceutical
clorarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with clorarabine.Investigational
ClotrimazoleThe metabolism of Cabazitaxel can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Clozapine.Approved
CobicistatThe serum concentration of Cabazitaxel can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Cabazitaxel.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cabazitaxel.Approved
ColforsinThe serum concentration of Cabazitaxel can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Cabazitaxel can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Cabazitaxel.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cordycepin.Investigational
CrenolanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Crenolanib.Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Curcumin.Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cabazitaxel.Approved, Investigational
CyclosporineThe metabolism of Cabazitaxel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cytarabine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cabazitaxel.Approved
DabrafenibThe serum concentration of Cabazitaxel can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Cabazitaxel can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dactinomycin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Cabazitaxel.Approved
DaratumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Daratumumab.Approved
DarunavirThe serum concentration of Cabazitaxel can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Cabazitaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Cabazitaxel.Approved
DecitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Cabazitaxel can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Cabazitaxel can be decreased when combined with Delavirdine.Approved
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Cabazitaxel.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Deoxyspergualin.Investigational
DesipramineThe serum concentration of Cabazitaxel can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cabazitaxel.Approved
DesloratadineThe serum concentration of Cabazitaxel can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dexrazoxane.Approved, Withdrawn
DextromethorphanThe serum concentration of Cabazitaxel can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Cabazitaxel.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Cabazitaxel can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienogestThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dienogest.Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Diethylstilbestrol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Cabazitaxel.Approved
DihydroergotamineThe metabolism of Cabazitaxel can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Cabazitaxel.Illicit
DiindolylmethaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Diindolylmethane.Investigational
DiltiazemThe metabolism of Cabazitaxel can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dinutuximab.Approved
DipyridamoleThe serum concentration of Cabazitaxel can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabazitaxel.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Cabazitaxel.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Cabazitaxel can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Cabazitaxel can be increased when it is combined with Doxepin.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Doxifluridine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cabazitaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Cabazitaxel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Cabazitaxel can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Cabazitaxel can be decreased when combined with Dronedarone.Approved
EcabetThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ecabet.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cabazitaxel.Approved
efaproxiralThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with efaproxiral.Investigational
EfavirenzThe serum concentration of Cabazitaxel can be decreased when it is combined with Efavirenz.Approved, Investigational
EflornithineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eflornithine.Approved, Withdrawn
EG009The risk or severity of adverse effects can be increased when Cabazitaxel is combined with EG009.Investigational
ElbasvirThe serum concentration of Cabazitaxel can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Cabazitaxel.Approved, Investigational
ElsamitrucinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Elsamitrucin.Investigational
EnalaprilThe serum concentration of Cabazitaxel can be increased when it is combined with Enalapril.Approved, Vet Approved
EndostatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Endostatin.Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Enoxacin.Approved
EnrofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Enrofloxacin.Vet Approved
EntinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Cabazitaxel can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Cabazitaxel.Approved, Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epirubicin.Approved
EpofolateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epofolate.Investigational
Epothilone BThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Epothilone B.Experimental, Investigational
ErgonovineThe serum concentration of Cabazitaxel can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Cabazitaxel can be increased when it is combined with Ergotamine.Approved
EribulinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Cabazitaxel can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Cabazitaxel can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Cabazitaxel.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Estramustine.Approved
EstriolThe serum concentration of Cabazitaxel can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Estrone.Approved
EtanidazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Etanidazole.Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Cabazitaxel.Approved
Ethiodized oilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethiodized oil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ethyl carbamate.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Etoposide.Approved
EtravirineThe serum concentration of Cabazitaxel can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cabazitaxel.Approved
ExatecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Exatecan.Investigational
ExemestaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Exemestane.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Cabazitaxel.Approved
FelodipineThe serum concentration of Cabazitaxel can be increased when it is combined with Felodipine.Approved, Investigational
FenretinideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fenretinide.Investigational
FentanylThe serum concentration of Cabazitaxel can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Cabazitaxel.Approved
FexofenadineThe serum concentration of Cabazitaxel can be increased when it is combined with Fexofenadine.Approved
FiacitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fiacitabine.Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Cabazitaxel.Approved
FingolimodCabazitaxel may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlavopiridolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flavopiridol.Experimental, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fleroxacin.Approved
FloxuridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Floxuridine.Approved
FluconazoleThe metabolism of Cabazitaxel can be decreased when combined with Fluconazole.Approved
FludarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fludarabine.Approved
FlumequineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flumequine.Withdrawn
FluorouracilThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Cabazitaxel can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Cabazitaxel can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Cabazitaxel can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Cabazitaxel can be increased when it is combined with Flurazepam.Approved, Illicit
FlutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Flutamide.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Cabazitaxel.Approved
FluvoxamineThe metabolism of Cabazitaxel can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Formestane.Approved, Investigational, Withdrawn
FormycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Formycin.Experimental
FosamprenavirThe metabolism of Cabazitaxel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cabazitaxel can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Cabazitaxel can be increased when combined with Fosphenytoin.Approved
FotemustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fotemustine.Experimental
FulvestrantThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fulvestrant.Approved, Investigational
FumagillinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Fumagillin.Experimental
Fusidic AcidThe serum concentration of Cabazitaxel can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with G17DT.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gallium nitrate.Approved, Investigational
GarenoxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gatifloxacin.Approved, Investigational
GefitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Geldanamycin.Experimental
GemcitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemcitabine.Approved
GemfibrozilThe metabolism of Cabazitaxel can be decreased when combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GenisteinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Cabazitaxel is combined with GI-5005.Investigational
Ginsenoside CThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ginsenoside C.Nutraceutical
GlyburideThe serum concentration of Cabazitaxel can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Cabazitaxel can be increased when it is combined with Glycerol.Experimental
GoserelinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Goserelin.Approved
Gramicidin DThe serum concentration of Cabazitaxel can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Cabazitaxel.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Grepafloxacin.Withdrawn
GusperimusThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gusperimus.Investigational
HadacidinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hadacidin.Experimental
HalofuginoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Halofuginone.Investigational, Vet Approved
HaloperidolThe serum concentration of Cabazitaxel can be increased when it is combined with Haloperidol.Approved
HexestrolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hexestrol.Withdrawn
HydrocortisoneThe serum concentration of Cabazitaxel can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hydroxyprogesterone caproate.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hydroxyurea.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ibrutinib.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Cabazitaxel.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Cabazitaxel can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ifosfamide.Approved
Il 4The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Il 4.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Imatinib.Approved
ImipramineThe serum concentration of Cabazitaxel can be increased when it is combined with Imipramine.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Imiquimod.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Cabazitaxel.Approved
IndinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Indinavir.Approved
IndirubinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Indirubin.Investigational
IndomethacinThe serum concentration of Cabazitaxel can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Cabazitaxel is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Cabazitaxel is combined with INGN 225.Investigational
Interferon beta-1aThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon beta-1a.Approved, Investigational
Interferon beta-1bThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon beta-1b.Approved
IobenguaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Iobenguane.Approved
IpilimumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ipilimumab.Approved
IrbesartanThe metabolism of Cabazitaxel can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Irinotecan.Approved, Investigational
IrofulvenThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Irofulven.Investigational
IsavuconazoniumThe metabolism of Cabazitaxel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Cabazitaxel can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cabazitaxel can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Cabazitaxel can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ixabepilone.Approved, Investigational
IxazomibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ixazomib.Approved
KetamineThe serum concentration of Cabazitaxel can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Cabazitaxel.Approved
KetoconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Ketoconazole.Approved, Investigational
KOS-1584The risk or severity of adverse effects can be increased when Cabazitaxel is combined with KOS-1584.Investigational
L-alanosineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with L-alanosine.Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Cabazitaxel.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cabazitaxel.Approved, Investigational
LanreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lanreotide.Approved
LansoprazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cabazitaxel.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenalidomide.Approved
LenvatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenvatinib.Approved
LetrozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Letrozole.Approved, Investigational
LeuprolideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Cabazitaxel.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Cabazitaxel.Approved
LevothyroxineThe serum concentration of Cabazitaxel can be decreased when it is combined with Levothyroxine.Approved
LiarozoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Liarozole.Investigational
LidocaineThe serum concentration of Cabazitaxel can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Cabazitaxel.Approved
LiothyronineThe serum concentration of Cabazitaxel can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Cabazitaxel can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Cabazitaxel can be increased when it is combined with Lisinopril.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Cabazitaxel can be increased when it is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lomustine.Approved
LonidamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lonidamine.Approved, Investigational
LoperamideThe serum concentration of Cabazitaxel can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Cabazitaxel can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Cabazitaxel can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Cabazitaxel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Cabazitaxel can be increased when it is combined with Lumacaftor.Approved
Ly2801653The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ly2801653.Investigational
LycopeneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lycopene.Approved
MafosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mafosfamide.Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Cabazitaxel.Approved, Investigational
MaprotilineThe serum concentration of Cabazitaxel can be increased when it is combined with Maprotiline.Approved
MasitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Masitinib.Vet Approved
MasoprocolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Masoprocol.Approved
MaxacalcitolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Maxacalcitol.Approved
MDX-1106The risk or severity of adverse effects can be increased when Cabazitaxel is combined with MDX-1106.Investigational
MebendazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mebendazole.Approved, Vet Approved
MechlorethamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mechlorethamine.Approved
MedrogestoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Cabazitaxel can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Megestrol acetate.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Melphalan.Approved
MeprobamateThe serum concentration of Cabazitaxel can be increased when it is combined with Meprobamate.Approved, Illicit
MequinolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mequinol.Approved
MercaptopurineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mercaptopurine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Cabazitaxel.Withdrawn
MethadoneThe serum concentration of Cabazitaxel can be increased when it is combined with Methadone.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methotrexate.Approved
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methyl aminolevulinate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Methyltestosterone.Approved
MetoprololThe serum concentration of Cabazitaxel can be increased when it is combined with Metoprolol.Approved, Investigational
MGI-114The risk or severity of adverse effects can be increased when Cabazitaxel is combined with MGI-114.Investigational
MibefradilThe serum concentration of Cabazitaxel can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Cabazitaxel can be decreased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Midostaurin.Investigational
MifepristoneThe serum concentration of Cabazitaxel can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Miltefosine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Cabazitaxel.Approved
MisonidazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Misonidazole.Investigational
MitoguazoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitoguazone.Investigational
MitolactolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitolactol.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitomycin.Approved
MitotaneThe serum concentration of Cabazitaxel can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mizoribine.Investigational
MLN576The risk or severity of adverse effects can be increased when Cabazitaxel is combined with MLN576.Investigational
ModafinilThe serum concentration of Cabazitaxel can be decreased when it is combined with Modafinil.Approved, Investigational
MolgramostimThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Molgramostim.Investigational
MorphineThe serum concentration of Cabazitaxel can be increased when it is combined with Morphine.Approved, Investigational
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with motexafin gadolinium.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cabazitaxel.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolic acid.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Cabazitaxel.Approved
NafcillinThe serum concentration of Cabazitaxel can be decreased when it is combined with Nafcillin.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nalidixic Acid.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cabazitaxel.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Cabazitaxel.Approved, Vet Approved
NaltrexoneThe serum concentration of Cabazitaxel can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NamitecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Namitecan.Investigational
NaringeninThe serum concentration of Cabazitaxel can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.Approved, Investigational
NavitoclaxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Navitoclax.Investigational
NecitumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Necitumumab.Approved
NedaplatinNedaplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
NefazodoneThe serum concentration of Cabazitaxel can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nelarabine.Approved, Investigational
NelfinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Cabazitaxel can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Cabazitaxel can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cabazitaxel can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Cabazitaxel can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Cabazitaxel can be decreased when it is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nilotinib.Approved, Investigational
NilutamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nilutamide.Approved
NimustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nimustine.Investigational
NintedanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nintedanib.Approved
NisoldipineThe serum concentration of Cabazitaxel can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Cabazitaxel can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Cabazitaxel can be increased when it is combined with Nitrendipine.Approved
NivolumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nivolumab.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Cabazitaxel.Approved
Nk012The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nk012.Investigational
nocodazoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with nocodazole.Experimental
NolatrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nolatrexed.Investigational
NorethisteroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Norfloxacin.Approved
NOV-002NOV-002 may increase the myelosuppressive activities of Cabazitaxel.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Obinutuzumab.Approved
OctreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Octreotide.Approved, Investigational
OfatumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofatumumab.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Cabazitaxel.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Olaparib.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Omacetaxine mepesuccinate.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Cabazitaxel.Approved
OmeprazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OprelvekinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Cabazitaxel can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Cabazitaxel.Approved
OxaliplatinOxaliplatin may increase the myelosuppressive activities of Cabazitaxel.Approved, Investigational
P-NitrophenolThe serum concentration of Cabazitaxel can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabazitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Cabazitaxel can be increased when it is combined with Palbociclib.Approved
PalifosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Palifosfamide.Investigational
Palmitic AcidThe serum concentration of Cabazitaxel can be increased when it is combined with Palmitic Acid.Experimental
PamidronateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pamidronate.Approved
PanitumumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Cabazitaxel can be increased when it is combined with Paroxetine.Approved, Investigational
PARP inhibitorThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with PARP inhibitor.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cabazitaxel.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pegaspargase.Approved, Investigational
PembrolizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pemetrexed.Approved, Investigational
PenclomedineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Penclomedine.Investigational
PentobarbitalThe metabolism of Cabazitaxel can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pentostatin.Approved, Investigational
PerindoprilThe serum concentration of Cabazitaxel can be increased when it is combined with Perindopril.Approved
PertuzumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pertuzumab.Approved
PhenobarbitalThe metabolism of Cabazitaxel can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Phenylacetic acid.Approved
PhenytoinThe metabolism of Cabazitaxel can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cabazitaxel.Approved, Investigational
PimozideThe serum concentration of Cabazitaxel can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Cabazitaxel can be decreased when combined with Pioglitazone.Approved, Investigational
PipobromanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pipobroman.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirfenidone.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirlindole.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Cabazitaxel.Approved
PixantroneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pixantrone.Investigational
Platelet Activating FactorThe serum concentration of Cabazitaxel can be decreased when it is combined with Platelet Activating Factor.Experimental
PlevitrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Plevitrexed.Investigational
PlicamycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Plicamycin.Approved, Withdrawn
PodofiloxThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Podofilox.Approved
PodophyllinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Podophyllin.Approved
polyacrylic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with polyacrylic acid.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pomalidomide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ponatinib.Approved
PorfimerThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Porfimer.Approved, Investigational
porfiromycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with porfiromycin.Investigational
PosaconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pralatrexate.Approved
PravastatinThe serum concentration of Cabazitaxel can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Cabazitaxel can be increased when it is combined with Prazosin.Approved
PrednimustineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednimustine.Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Cabazitaxel can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Cabazitaxel can be increased when it is combined with Probenecid.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Procarbazine.Approved
ProgesteroneThe serum concentration of Cabazitaxel can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Cabazitaxel can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Cabazitaxel can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Cabazitaxel can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Cabazitaxel can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cabazitaxel.Approved
Purine RibosideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Purine Riboside.Experimental
PuromycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Puromycin.Experimental
PyrazoloacridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pyrazoloacridine.Investigational
Qlt091001The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Qlt091001.Investigational
QuercetinThe serum concentration of Cabazitaxel can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Cabazitaxel.Approved
QuinacrineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Quinacrine.Approved
QuinidineThe serum concentration of Cabazitaxel can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Cabazitaxel can be increased when it is combined with Quinine.Approved
RabeprazoleThe metabolism of Cabazitaxel can be decreased when combined with Rabeprazole.Approved, Investigational
Rabies vaccineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Cabazitaxel.Approved
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Raltitrexed.Approved, Investigational
RamucirumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ramucirumab.Approved, Investigational
RanibizumabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranibizumab.Approved
RanitidineThe serum concentration of Cabazitaxel can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cabazitaxel.Approved, Investigational
RanpirnaseThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ranpirnase.Investigational
ReboxetineThe serum concentration of Cabazitaxel can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Regorafenib.Approved
ReserpineThe serum concentration of Cabazitaxel can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Resveratrol.Experimental, Investigational
Rhodamine 6GThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rhodamine 6G.Experimental
RifabutinThe metabolism of Cabazitaxel can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cabazitaxel can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cabazitaxel can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cabazitaxel.Approved, Investigational
RilpivirineThe serum concentration of Cabazitaxel can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Cabazitaxel.Approved, Investigational
RitonavirThe serum concentration of Cabazitaxel can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Cabazitaxel.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Cabazitaxel.Approved
RolapitantThe serum concentration of Cabazitaxel can be increased when it is combined with Rolapitant.Approved
RomidepsinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Romidepsin.Approved, Investigational
RomiplostimThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Romiplostim.Approved
RoquinimexThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Roquinimex.Investigational
RosiglitazoneThe metabolism of Cabazitaxel can be decreased when combined with Rosiglitazone.Approved, Investigational
RubitecanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rubitecan.Investigational
RucaparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rucaparib.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ruxolitinib.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Cabazitaxel.Approved, Vet Approved
SalirasibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Salirasib.Investigational
SaquinavirThe serum concentration of Cabazitaxel can be increased when it is combined with Saquinavir.Approved, Investigational
SaracatinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Saracatinib.Investigational
SatraplatinSatraplatin may increase the myelosuppressive activities of Cabazitaxel.Investigational
ScopolamineThe serum concentration of Cabazitaxel can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Cabazitaxel can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Cabazitaxel can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Cabazitaxel.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seliciclib.Investigational
SemaxanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Semaxanib.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Seocalcitol.Experimental
SertralineThe serum concentration of Cabazitaxel can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Cabazitaxel can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cabazitaxel.Approved
SiltuximabThe serum concentration of Cabazitaxel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Cabazitaxel can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cabazitaxel.Approved
SirolimusThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Cabazitaxel.Approved, Investigational
Sodium phenylbutyrateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sodium phenylbutyrate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Cabazitaxel.Approved
SonidegibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sonidegib.Approved, Investigational
SonifilanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sonifilan.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparfloxacin.Approved
Sparfosic acidThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparfosic acid.Experimental
SparsomycinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparsomycin.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Cabazitaxel.Experimental
SpironolactoneThe serum concentration of Cabazitaxel can be increased when it is combined with Spironolactone.Approved
squalamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with squalamine.Investigational
SRP 299The risk or severity of adverse effects can be increased when Cabazitaxel is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Cabazitaxel is combined with SRT501.Investigational
St. John's WortThe serum concentration of Cabazitaxel can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Cabazitaxel can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Cabazitaxel can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Streptozocin.Approved
SulfamethoxazoleThe metabolism of Cabazitaxel can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Cabazitaxel can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Cabazitaxel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulforaphaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sulforaphane.Investigational
SulindacThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sulindac.Approved
SumatriptanThe serum concentration of Cabazitaxel can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sunitinib.Approved, Investigational
SuraminThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Suramin.Approved
SwainsonineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Swainsonine.Experimental
TacrineThe serum concentration of Cabazitaxel can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Cabazitaxel.Approved, Investigational
TacrolimusThe serum concentration of Cabazitaxel can be decreased when it is combined with Tacrolimus.Approved, Investigational
TalaporfinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Talaporfin.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Cabazitaxel can be increased when it is combined with Taurocholic Acid.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Cabazitaxel.Approved
TegafurThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tegafur.Approved
TelaprevirThe serum concentration of Cabazitaxel can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Cabazitaxel can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Cabazitaxel can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temafloxacin.Withdrawn
TemoporfinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temoporfin.Approved
TemozolomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Teniposide.Approved
TerazosinThe serum concentration of Cabazitaxel can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Cabazitaxel can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe metabolism of Cabazitaxel can be decreased when combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Cabazitaxel can be decreased when it is combined with Tesmilifene.Investigational
TestolactoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Testolactone.Approved
TestosteroneThe serum concentration of Cabazitaxel can be increased when it is combined with Testosterone.Approved, Investigational
TetrathiomolybdateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tetrathiomolybdate.Investigational
TezacitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tezacitabine.Investigational
TG4010The risk or severity of adverse effects can be increased when Cabazitaxel is combined with TG4010.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thiotepa.Approved
ThymalfasinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Thymalfasin.Approved, Investigational
TiboloneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Cabazitaxel.Approved
TiclopidineThe metabolism of Cabazitaxel can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Cabazitaxel.Approved
TioguanineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tioguanine.Approved
TipifarnibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tipifarnib.Investigational
TirapazamineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tirapazamine.Investigational
TivozanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tivozanib.Investigational
Tnp 470The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tnp 470.Investigational
TocilizumabThe serum concentration of Cabazitaxel can be decreased when it is combined with Tocilizumab.Approved
TofacitinibCabazitaxel may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Cabazitaxel.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cabazitaxel.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tositumomab.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trabectedin.Approved, Investigational
TrametinibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trametinib.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cabazitaxel.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trastuzumab emtansine.Approved
TrazodoneThe serum concentration of Cabazitaxel can be decreased when it is combined with Trazodone.Approved, Investigational
TreosulfanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Treosulfan.Investigational
TretazicarThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tretazicar.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tretinoin.Approved, Investigational, Nutraceutical
TrifluoperazineThe serum concentration of Cabazitaxel can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Cabazitaxel can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trifluridine.Approved
TrilostaneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Cabazitaxel can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Cabazitaxel can be increased when it is combined with Trimipramine.Approved
TriptorelinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Triptorelin.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trofosfamide.Investigational
TroleandomycinThe serum concentration of Cabazitaxel can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trovafloxacin.Approved, Withdrawn
TroxacitabineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Troxacitabine.Investigational
TTNPBThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with TTNPB.Experimental
TubercidinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tubercidin.Experimental
UbenimexThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ubenimex.Experimental
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Cabazitaxel.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Cabazitaxel.Approved
Uracil mustardThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Uracil mustard.Approved
VadimezanThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vadimezan.Investigational
Val 083The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Val 083.Investigational
ValrubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Valrubicin.Approved
VandetanibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vandetanib.Approved
VapreotideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vapreotide.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Cabazitaxel.Approved
VeliparibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Veliparib.Investigational
VemurafenibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Cabazitaxel.Approved
VenlafaxineThe metabolism of Cabazitaxel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Cabazitaxel can be decreased when combined with Verapamil.Approved
VerteporfinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Verteporfin.Approved, Investigational
VesnarinoneThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vesnarinone.Investigational
VinblastineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cabazitaxel.Approved, Investigational
VincristineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vindesine.Approved
VinflunineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinflunine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vinorelbine.Approved, Investigational
VintafolideThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vintafolide.Investigational
VismodegibThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vismodegib.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe serum concentration of Cabazitaxel can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Vorinostat.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Cabazitaxel.Approved
ZimelidineThe serum concentration of Cabazitaxel can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Cabazitaxel can be decreased when combined with Ziprasidone.Approved
ZorubicinThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Nagesh Palepu, “CABAZITAXEL FORMULATIONS AND METHODS OF PREPARING THEREOF.” U.S. Patent US20120065255, issued March 15, 2012.

US20120065255
General References
  1. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK: Cabazitaxel. Nat Rev Drug Discov. 2010 Sep;9(9):677-8. doi: 10.1038/nrd3254. [PubMed:20811375 ]
  2. Kort A, Hillebrand MJ, Cirkel GA, Voest EE, Schinkel AH, Rosing H, Schellens JH, Beijnen JH: Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Apr 15;925:117-23. doi: 10.1016/j.jchromb.2013.02.034. Epub 2013 Mar 5. [PubMed:23542607 ]
  3. Nightingale G, Ryu J: Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. P T. 2012 Aug;37(8):440-8. [PubMed:23091336 ]
External Links
ATC CodesL01CD04
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (383 KB)
MSDSDownload (99.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9535
Blood Brain Barrier-0.9825
Caco-2 permeable-0.7945
P-glycoprotein substrateSubstrate0.8287
P-glycoprotein inhibitor IInhibitor0.6646
P-glycoprotein inhibitor IIInhibitor0.5887
Renal organic cation transporterNon-inhibitor0.933
CYP450 2C9 substrateNon-substrate0.8236
CYP450 2D6 substrateNon-substrate0.882
CYP450 3A4 substrateSubstrate0.7256
CYP450 1A2 substrateNon-inhibitor0.8197
CYP450 2C9 inhibitorNon-inhibitor0.8654
CYP450 2D6 inhibitorNon-inhibitor0.8935
CYP450 2C19 inhibitorNon-inhibitor0.8429
CYP450 3A4 inhibitorNon-inhibitor0.6339
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9068
Ames testNon AMES toxic0.8028
CarcinogenicityNon-carcinogens0.9264
BiodegradationNot ready biodegradable0.9926
Rat acute toxicity2.6378 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.7906
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Kit
SolutionIntravenous40 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5438072 No2010-06-172013-11-22Us
US5698582 No2010-06-172012-07-03Us
US5847170 No2001-03-262021-03-26Us
US6331635 No1996-03-262016-03-26Us
US6372780 No1996-03-262016-03-26Us
US6387946 No1996-03-262016-03-26Us
US7241907 No2005-12-102025-12-10Us
US8927592 No2010-10-272030-10-27Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00413 mg/mLALOGPS
logP3.69ALOGPS
logP4.2ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)11.97ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area202.45 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity213.4 m3·mol-1ChemAxon
Polarizability86.39 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassDiterpenoids
Direct ParentTaxanes and derivatives
Alternative Parents
Substituents
  • Taxane diterpenoid
  • Phenylpropylamine
  • Benzoate ester
  • Tricarboxylic acid or derivatives
  • Benzylether
  • Benzoic acid or derivatives
  • Benzoyl
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Monosaccharide
  • Monocyclic benzene moiety
  • Acetate salt
  • Tertiary alcohol
  • Cyclic alcohol
  • Secondary alcohol
  • Oxetane
  • Ketone
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBA4A
Uniprot ID:
P68366
Molecular Weight:
49923.995 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
TUBB1
Uniprot ID:
Q9H4B7
Molecular Weight:
50326.56 Da
References
  1. JEVTANA [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. JEVTANA [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. JEVTANA [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. JEVTANA [Link]
Comments
comments powered by Disqus
Drug created on September 14, 2010 10:21 / Updated on December 02, 2016 02:43